Cytoreductive prostatectomy had gained a lot of interest in treatment of metastatic prostate cancer (mPCa) but this treatment approach is still in the experimental phase. This systematic review and meta-analysis was conducted to shed light on the merits of cytoreductive radical prostatectomy compared to systemic and radiation therapy in treatment of mPCa. In February 2021, summary data from 12 original research papers covering 100,973 patients is abstracted. PubMed/Medline, Scopus, Google Scholar, EMBASE, and the Cochrane Library were all reviewed and 12 publications were chosen for inclusion. The evaluated outcomes were 1-, 3-, and 5-year Cancer-Specific (CSS) and overall survival (OS) rates. Cytoreductive radical prostatectomy had significantly higher survival rate for 1-year (OR: 3.03; 95% CI: 2.30–3.98; p < 0.001), 3-year (OR: 2.47; 95% CI: 2.14–3.51; p < 0.001), and 5-year CSS rates (OR: 2.90; 95% CI: 2.10–4.01; p < 0.001) than systemic therapy in mPCa. Higher significant rates of 1-year (OR: 2.35; 95% CI: 1.65–3.36; p < 0.001), three-year (OR: 2.25; 95% CI: 1.96–2.60; p < 0.001), and 5-year OS rates (OR: 2.54; 95% CI: 2.10–3.08; p < 0.001) were also detected for cytoreductive radical prostatectomy compared to systemic therapy. There were no significant differences in 1-year (OR: 1.21; 95% CI: 0.88–1.66; p = 0.25), 3-year (OR: 1.21; 95% CI: 0.92–1.59; p = 0.18), and 5-year CSS rates (OR: 0.91; 95% CI: 0.58–1.42; p = 0.67) between cytoreductive radical prostatectomy and radiation in mPCa patients. Also, no significant differences in 1-year (OR: 1.06; 95% CI: 0.77–1.47; p = 0.71), 3-year (OR: 0.83; 95% CI: 0.60–1.14; p = 0.25), and 5-year OS rates (OR: 1.84; 95% CI: 0.76–4.45; p = 0.18) were detected between cytoreductive radical prostatectomy and radiation therapy. Cytoreductive radical prostatectomy had significantly higher 1-, 3-, and 5-year CSS and OS rates compared to systemic therapy. Comparable CSS and OS rates were found between cytoreductive radical prostatectomy and radiation therapy.
A Systematic Review of Patients’ Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer
